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Abstract
Background: We aimed to determine the extent of post-treatment weight gain that occurs in pediatric patients in
the first year following radioactive iodine (RAI) therapy for Graves disease (GD) and its relationship to clinical
characteristics.
Methods: A retrospective chart review of patients receiving RAI therapy for GD between 1998–2015 was
performed. Change in BMI SDS (ΔBMI SDS) from baseline to one year after treatment was determined. We also
investigated whether individual clinical and/or biochemical factors were associated with the weight trajectory in
these patients.
Results: One hundred fifty seven patients aged 12.7 ± 3 years (80% girls) were included in the analysis. Average
ΔBMI SDS was 0.70 ± 0.71 (p < 0.001) at 1 year. Patients with weight loss at presentation had a greater ΔBMI SDS
than those without (0.92 vs 0.56, p = 0.005), whereas no association was seen with gender, pubertal status, use of
antithyroid drugs, history of ADHD, or Down syndrome. Baseline BMI SDS was negatively correlated with ΔBMI SDS,
with a stronger correlation in males. From baseline to 1 year, the proportion of overweight and obese patients
increased from 9.6% to 18.5% and from 6.4% to 21%, respectively. In a subset of 81 patients, a positive correlation
was noted between time to euthyroidism and ΔBMI SDS, particularly in boys.
Conclusions: The number of our patients in the overweight category doubled and the number in the obese
category more than tripled in the first year following RAI treatment for GD. Anticipatory guidance regarding this
important issue is badly needed.
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Background
Graves disease (GD), characterized by autoimmune over-
stimulation of the thyroid gland, is the most common
cause of hyperthyroidism in children and adolescents
[1–4]. The overall incidence within the pediatric popula-
tion is approximately 1 in 10,000 [5] with the highest
prevalence seen in adolescent girls [2]. Although the hy-
permetabolic state in GD typically results in weight loss,
stable weight or even weight gain due to increased cal-
oric intake can be seen [5].
Therapeutic modalities for the treatment of GD in-
clude surgery, radioactive iodine (RAI) ablation and
anti-thyroid drugs (ATDs). Surgery and RAI are
considered definitive therapy and result in permanent
hypothyroidism. Patients receiving definitive therapy
often become hypothyroid for a period of time before
appropriate levothyroxine replacement and biochemical
euthyroidism is achieved. Weight gain following treat-
ment of GD has been reported in both children and
adults. Proposed explanations include continued in-
creased caloric consumption with resolution of the prior
hypermetabolic state [5], a return to or exaggeration of
premorbid weight [6], or a result of post-treatment
hypothyroidism [7]. Previous studies reporting change in
weight following treatment of GD in children have fo-
cused primarily on patients treated with ATDs as first-
line therapy. In contrast, the change in BMI after RAI
treatment has not been systematically studied. It is un-
known whether the treatment modality itself affects the
degree of weight gain or whether there are clinical or
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biochemical factors that might modulate the degree of
weight gain in these patients [7–9].
Thus, the goal of our study was to investigate the de-
gree of weight gain in the first year following RAI ther-
apy for GD. We also sought to explore whether
individual characteristics were associated with differ-
ences in weight gain among our patients.
Methods
Following ethical review and approval of Protocol
#1412088318 by the Indiana University Institutional
Review Board, a retrospective chart review was per-
formed of pediatric patients receiving RAI ablation for
GD at Riley Hospital for Children between 1998 and
2015. All patients with a documented height and weight
within four months before RAI treatment and a follow
up visit with documented height and weight between 6
and 18 months after RAI date were included. Regardless
of whether patients had been treated for GD prior to
evaluation at our institution, all patients were hyperthy-
roid at the time of RAI. If a second dose of RAI was
needed, the dose leading to successful ablation (i.e. the
second dose) was used as the event of interest to deter-
mine pre- and post-treatment height and weight.
Medical records were searched for variables of inter-
est, which included age, gender, pubertal status, history
of weight loss, DS (Down Syndrome), use of medications
for ADHD, ATD use for ≥ one month prior to RAI, start
date of levothyroxine replacement, and the date of docu-
mented euthyroidism. Weight and height were collected
at baseline (last appointment prior to RAI) and at the
one-year follow up appointment. BMI was calculated
using the formula {BMI = weight in kilograms/height in
meters2}. Pubertal status was classified as either pre-
pubertal (Tanner I) or pubertal (Tanner II-V). Euthyroid-
ism was considered to be a TSH and free T4 or total T4
within the performing laboratory’s reference range, or
(in a small subset of cases), documented interpretation
of lab tests as “normal” by the primary endocrinologist.
All BMIs were categorized according to Centers for
Disease Control (CDC) standards as underweight (<5th
percentile), normal weight (5- < 85th percentile), over-
weight (85- < 95th percentile) or obese (≥95th percentile)
[10]. Time to euthyroidism (TTE) was calculated by de-
termining the time in weeks between the date of starting
levothyroxine replacement and the date of documented
euthyroidism.
Statistics
Analyses were performed using SPSS statistical software
(version 24; IBM Corp.). All variables of interest were
evaluated for normality to determine appropriateness of
statistical methods and found to be normally distributed.
Descriptive statistics were used to report anthropometric
data and time intervals. Chi-square tests and Fisher’s
exact tests were used to analyze differences in weight
status category distribution before and after RAI. Paired
t-tests were used to assess differences in BMI before and
after treatment. Unpaired t-tests were used to analyze
the effect of clinical risk factors on weight gain. Linear
regression was used to describe strength of association
between change (Δ) in BMI SDS over time and contrib-
uting factors. The level of significance was α = 0.05, with
all p-values lower than 0.05 considered statistically sig-
nificant. Results are expressed as mean ± SD in the text,
with medians and ranges also provided in Table 1.
Results
Of 247 patients receiving RAI for GD, 157 (79.6% fe-
male) had complete data and were included in the ana-
lysis. Mean baseline age was 12.7 ± 3.0 years and mean
baseline BMI SDS was 0.003 ± 1.18 kg/m2. Ten patients
(6.4%) had DS (Down Syndrome) and 33 (21.0%) had re-
ceived ATDs before RAI ablation. Of 135 patients with
documented pubertal status, 88 (65.2%) were ≥Tanner
stage II at the baseline evaluation. Post-treatment BMI
data were obtained at 50.65 ± 11.32 weeks after RAI.
Average ΔBMI SDS from baseline to one year was
0.70 ± 0.71 (p < 0.001), with no difference noted by gen-
der, pubertal status, history of ATDs, use of stimulant
medications for ADHD, or presence of DS (Down
Syndrome). In contrast, BMI SDS increased more in
those with a history of weight loss (ΔBMI SDS 0.92 vs
0.56, p = 0.005). These results are shown in Table 1. On
regression analysis, baseline BMI SDS was negatively
correlated with ΔBMI SDS (p < 0.001, R = −0.529), with
a stronger correlation in males (p < 0.001, R = −0.696).
From baseline to follow-up, the proportion of under-
weight patients in the study decreased from 10.2% to 0.6%
(p ≤ 0.001), while those in the overweight and obese cat-
egories increased from 9.6% to 18.5% (p ≤ 0.001) and from
6.4% to 21% (p ≤ 0.001), respectively, as shown in Fig. 1.
Of 157 patients, 2 (0.1%) moved into a lower weight cat-
egory, while 62 (39.5%) moved into a higher weight cat-
egory. Notably, nearly one third of our patients (31.2%)
moved into the overweight or obese category from a lower
weight category.
A sub-analysis was performed on 81 patients (85.2%
female) with evidence of good compliance in whom
the exact TTE was available. Within this group, TTE
was 24.16 ± 13.28 weeks and ΔBMI SDS at one year
was not different from the group as a whole. Unlike
what was seen for the entire cohort, a history of
weight loss had no impact on ΔBMI SDS by 1 year,
(0.77 ± 0.62 vs. 0.55 ± 0.56, p = 0.12), whereas pre-
pubertal patients were found to have greater ΔBMI
SDS than pubertal patients at 1 year (0.90 ± .71 vs
0.57 ± 0.58, p = 0.037). In males, a longer TTE was
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correlated with greater increase in BMI z-score (R = 0.63,
p = 0.029) (Fig. 2), while a similar, though weaker, associ-
ation was seen in females (R = 0.59, p ≤ 0.001).
Discussion
Weight gain after treatment for GD is well recognized in
adults, but only two previous studies have been pub-
lished in pediatric patients to our knowledge [5, 11].
These studies included patients who were almost exclu-
sively treated with ATDs as first-line therapy, and did
not closely examine as many potential modifying factors.
We observed a ΔBMI SDS of 0.70 ± 0.71 over the first
year in our population receiving RAI therapy as defini-
tive treatment for GD. One previous study followed
children for up to 3 years and observed a similar
increase in BMI z-score after treatment from −0.02 ± 1.05
to 0.79 ± 0.81 with subsequent stabilization of weight, with
most weight gain seen within the first 6 months of treat-
ment [5]. A second study comparing changes in weight
following treatment of both hypothyroidism and hyper-
thyroidism also reported weight gain after treatment for
GD early in follow up, though the exact time frame was
not specified [11].
Unsurprisingly, a history of weight loss before RAI was
associated with greater weight gain at follow up in our
population, though this relationship was not present in
the sub-analysis. However, prepubertal patients in our
sub-analysis did have a greater ΔBMI SDS. This is in line
with another study that observed greater increases in
Table 1 Potential factors associated with weight gain in patients following RAI treatment of GD
Variable – Mean ± SD
Median (range)
Whole population (n = 157) Sub-analysis (n = 81)
Age 12.68 ± 3.00 y 12.79 ± 3.02 y
12.86 (5.34-17.89) y 12.77 (5.34-17.83) y
ΔBMI SDS p-value ΔBMI SDS p-value
Gender Female (%)
0.71 ± 0.66 (79.6)
Male (%)
0.71 ± 0.92 (20.4)
0.99 Female (%)
0.69 ± 0.65 (85.2)
Male (%)
0.35 ± 0.47 (14.8)
0.09
0.61 (−0.4-2.97) 0.41 (−0.55-3.85) 0.69 (−0.4-2.68) 0.24 (−0.55-1.24)
Yes (%) No (%) Yes (%) No (%)
ATD use 0.64 ± 0.68 (21) 0.73 ± 0.73 (79) 0.55 0.67 ± 0.77 (18.5) 0.63 ± 0.60 (81.5) 0.81
0.46 (−0.37-2.68) 0.54 (−0.55-3.85) 0.55 (−0.25-2.68) 0.66 (−0.55-2.04)
Down syndrome 0.85 ± 0.86 (6.4) 0.70 ± 0.71 (93.6) 0.53 1.04 ± 0.90 (7.4) 0.61 ± 0.60 (92.6) 0.10
0.88 (0.0-2.68) 0.53 (−0.55-3.85) 0.88 (0.17-2.68) 0.59 (−0.55-2.04)
ADHD treatment 0.97 ± 1.08 (7.6) 0.69 ± 0.68 (92.4) 0.40 0.98 ± 0.79 (4.9) 0.62 ± 0.62 (95.1) 0.26
0.44 (0.08-3.85) 0.55 (−0.55-2.97) 0.97 (0.08-1.92) 0.59 (−0.55-2.68)
History of weight loss 0.92 ± 0.84 (38.2) 0.56 ± 0.57 (49) 0.005* 0.77 ± 0.62 (39.5) 0.55 ± 0.56 (50.6) 0.12
0.74 (−0.55-3.85) 0.45 (−0.4-2.47) 0.74 (−0.55-2.00) 0.57 (−0.4-2.04)
Pubertal 0.67 ± 0.63 (56.1) 0.91 ± 0.90 (29.9) 0.10 0.57 ± 0.58 (56.8) 0.90 ± 0.71 (29.6) 0.04*
0.49 (−0.4-2.71) 0.75 (−0.37-3.85) 0.50 (−0.4-2.04) 0.82 (−0.35-2.68)
Significant findings (p < 0.05) are marked with an asterisk (*). Mean ± SD are on line 1 and median, range on line 2 for all variables. Not all percentages
add to 100% due to missing patient information. BMI = body mass index; ATD = anti-thyroid drug; ADHD = attention deficit-hyperactivity disorder
Fig. 1 BMI classification of patients with Graves disease before and
1 year after RAI treatment. * = p < 0.01; ** = p < 0.001 Fig. 2 Relationship of ΔBMI SDS to time to euthyroidism in boys
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BMI after treatment for GD in children under 11 years
compared with older children [5]. It is unknown whether
this relationship is a result of age or of the metabolic
changes that occur during puberty. No other factors
were found to clearly define higher-risk groups for
weight gain in our population. All patients receiving RAI
for GD should be considered at high risk for weight gain
and counseled accordingly.
Although our study was focused on the effects of RAI
therapy, 21% of patients had previously received ATDs
and experienced no difference in ΔBMI SDS at one year
compared with those who had not. Most patients treated
with ATDs were not seen at our institution at their ini-
tial presentation with GD, and thus their pre-treatment
BMIs were not available. However, previous research has
suggested that the use of sequential treatment modalities
in adults can result in continued weight gain compared
with definitive treatment as a first line approach [8].
This question would be interesting to investigate in
pediatric patients as well. If corroborated, this may be
further reason to advocate for earlier definitive treat-
ment rather than pursuing medical therapy which only
rarely results in permanent remission in children and
adolescents and carries the potential for rare but serious
side effects [12].
While TTE was negatively correlated with ΔBMI SDS
in our subanalysis, the weakness of this association sug-
gests that other factors should also be considered.
Though some studies in adults show differences in BMI
outcome by treatment modality [8, 9], this has not been
demonstrated consistently, and it is unknown whether
these expectations can be extended to children. We
found similar outcomes in our population when com-
pared to reports from other centers [5].
To our knowledge, our study represents the largest co-
hort of pediatric patients in whom weight gain following
treatment for GD is investigated, and the only one in
which all patients were treated with RAI. Limitations in-
clude its retrospective nature as well as the fact that data
documenting the precise TTE was only available in 81 of
our patients. An additional weakness is that we did not
have information regarding our patients’ BMIs prior to
the development of GD. However, nearly 40% of our
patients were either overweight or obese at one year, a
rate above national BMI SDS data in youth 2–19 years
of age [13].
Conclusions
In conclusion, we observed a striking and nearly univer-
sal increase in BMI SDS one year after RAI treatment
for GD resulting in a doubling in the number of over-
weight and a tripling in the number of obese patients,
placing them at higher risk for adverse health conse-
quences over time. Future studies should focus on
targeted interventions aimed at attenuating the rate of
weight gain in children and adolescents undergoing
treatment for GD.
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